YKL-40 in pediatric asthma, MUC5B promoter polymorphism in idiopathic pulmonary fibrosis, and esmolol in septic shock
- PMID: 24787067
- PMCID: PMC5446197
- DOI: 10.1164/rccm.201312-2253RR
YKL-40 in pediatric asthma, MUC5B promoter polymorphism in idiopathic pulmonary fibrosis, and esmolol in septic shock
Comment on
-
The chitinase-like protein YKL-40: a possible biomarker of inflammation and airway remodeling in severe pediatric asthma.J Allergy Clin Immunol. 2013 Aug;132(2):328-35.e5. doi: 10.1016/j.jaci.2013.03.003. Epub 2013 Apr 26. J Allergy Clin Immunol. 2013. PMID: 23628340
-
Association between the MUC5B promoter polymorphism and survival in patients with idiopathic pulmonary fibrosis.JAMA. 2013 Jun 5;309(21):2232-9. doi: 10.1001/jama.2013.5827. JAMA. 2013. PMID: 23695349 Free PMC article.
-
Effect of heart rate control with esmolol on hemodynamic and clinical outcomes in patients with septic shock: a randomized clinical trial.JAMA. 2013 Oct 23;310(16):1683-91. doi: 10.1001/jama.2013.278477. JAMA. 2013. PMID: 24108526 Clinical Trial.
References
-
- Konradsen JR, James A, Nordlund B, Reinius LE, Söderhäll C, Melén E, Wheelock AM, Lödrup Carlsen KC, Lidegran M, Verhoek M, et al. The chitinase-like protein YKL-40: a possible biomarker of inflammation and airway remodeling in severe pediatric asthma J Allergy Clin Immunol 2013132328–335.e5 - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
